This is the first proof of concept study for OC000459 and is undertaken to assess the effects
of the compound on the development of inflammatory cytokines in a model (nasal allergen
challenge model) that is validated and clinically safe and easy to conduct. OC000459 will be
compared with placebo in the study.
The study will be a randomised, double blind, placebo controlled, crossover evaluation of the
effect of OC000459 on cytokine secretion induced by nasal allergen challenge. Male subjects
with a known history of allergic rhinitis and screening positive to allergen will be
included. After dosing with OC000459 or placebo, nasal allergen challenge will be performed
and measurements made in the nasal fluids. Nasal symptom scores will also be recorded. Safety
parameters will be monitored throughout.